Following a full submission
AWMSG advice |
|
| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2018. Refer to HST27: Afamelanotide for treating erythropoietic protoporphyria for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|
Medicine details |
|
| Medicine name | afamelanotide (Scenesse®) |
| Formulation | 16 mg subcutaneous implant |
| Reference number | 634 |
| Indication | Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) |
| Company | Clinuvel Pharmaceuticals Ltd |
| BNF chapter | Skin |
| Submission type | Full |
| Status | Superseded |
| Advice number | 1717 |
| NMG meeting date | 03/05/2017 |
| AWMSG meeting date | 13/09/2017 |
| Date of issue | 22/03/2018 |
| NICE guidance | HST27: Afamelanotide for treating erythropoietic protoporphyria |